© Copyright RiverVest® All Rights Reserved.
/ PORTFOLIO
San Francisco, CA
IPO July 2018 (NASDAQ: ALLK)
Allakos is a clinical-stage biotechnology company developing therapeutic antibodies targeting a broad range of allergic, inflammatory, and proliferative diseases. The Company’s lead antibody, AK002, targets Siglec-8, an inhibitory receptor on human mast cells and eosinophils.